GlassScriptPhysician profile
Mara Knoche
NPI 1245693068
$1,962.56
in general payments reported to CMS, 2019-2025
26 companies · $968 in 2025
The $968 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $995 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.75 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $231.53 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $155.28 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $151.72 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $144.12 | 2024-2025 | |
| Amgen INC. | $105.36 | 2024-2025 | Otezla, Repatha, Repatha |
| Organon LLC | $97.43 | 2024-2025 | Nexplanon |
| Vanda Pharmaceuticals INC. | $95.69 | 2025 | Fanapt |
| Pfizer INC. | $94.27 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $86.79 | 2024-2025 | Farxiga, Breztri |
| Abbvie INC. | $68.05 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $61.57 | 2024-2025 | Voquezna |
| Abbott Laboratories | $59.97 | 2024-2025 | Freestyle Libre 3 |
| Seqirus USA INC | $37.73 | 2024-2025 | Fluad, Flucelvax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.36 | 2024 | Jardiance, Tradjenta, Synjardy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $30.47 | 2024 | Uzedy, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $26.96 | 2024 | |
| Medtronic, INC. | $23.52 | 2024 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.43 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $19.62 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $19.41 | 2025 | Spravato |
| Insulet Corporation | $16.23 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $14.90 | 2024 | Gardasil, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.54 | 2024 | Xifaxan |
| Astellas Pharma US INC | $14.47 | 2024 | Veozah |
| Mylan Specialty L.P. | $13.39 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Knoche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.